Do analysts recommend TRAW or VCNX?

Traws Pharma currently has a consensus price target of $1.00, suggesting a potential upside of 30.26%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Traws Pharma is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, TRAW or VCNX?

Traws Pharma has higher revenue and earnings than Vaccinex. Traws Pharma is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Traws Pharma $2.79M 2.80 $9.17M -$1.69 N/A Vaccinex $388K 6.84 -$20.25M -$48.27 N/A

Is TRAW or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -913.18% -133.88% Vaccinex N/A N/A -383.58%

Do analysts recommend VCNX or RVPH?

Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 10,001.01%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is VCNX or RVPH more profitable?

Vaccinex's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media favor VCNX or RVPH?

In the previous week, Vaccinex and Vaccinex both had 1 articles in the media. Vaccinex's average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate VCNX or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, VCNX or ASBP?

Vaccinex has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaccinex $388K 6.84 -$20.25M -$48.27 N/A Aspire Biopharma $10K 807.30 -$24.48M -$116.67 N/A

Is VCNX or ASBP more profitable?

Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Aspire Biopharma N/A N/A -398.04%

Does the media prefer VCNX or ASBP?

In the previous week, Vaccinex and Vaccinex both had 1 articles in the media. Aspire Biopharma's average media sentiment score of 0.62 beat Vaccinex's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aspire Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HCWB or VCNX?

HCW Biologics presently has a consensus price target of $30.00, indicating a potential upside of 597.67%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts clearly believe HCW Biologics is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is HCWB or VCNX more profitable?

Vaccinex has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Vaccinex's return on equity of 0.00% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets HCW Biologics -34.73% -486.87% -29.19% Vaccinex N/A N/A -383.58%

Does the media refer more to HCWB or VCNX?

In the previous week, HCW Biologics had 8 more articles in the media than Vaccinex. MarketBeat recorded 9 mentions for HCW Biologics and 1 mentions for Vaccinex. HCW Biologics' average media sentiment score of 0.54 beat Vaccinex's score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PMCB or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PMCB or VCNX more profitable?

Nuvilex's return on equity of 2.13% beat Vaccinex's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 2.13% 1.69% Vaccinex N/A N/A -383.58%

Vaccinex (VCNX) Competitors

$1.02 0.00 (0.00%)

As of 07/1/2026

Compare

VCNX vs. TRAW, RVPH, ASBP, HCWB, and PMCB

Should you buy Vaccinex stock or one of its competitors? MarketBeat compares Vaccinex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vaccinex include Traws Pharma (TRAW), Reviva Pharmaceuticals (RVPH), Aspire Biopharma (ASBP), HCW Biologics (HCWB), and Nuvilex (PMCB). These companies are all part of the "pharmaceutical products" industry.

How does Vaccinex compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Traws Pharma has higher revenue and earnings than Vaccinex. Traws Pharma is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	2.80	$9.17M	-$1.69	N/A
Vaccinex	$388K	6.84	-$20.25M	-$48.27	N/A

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Traws Pharma currently has a consensus price target of $1.00, suggesting a potential upside of 30.26%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Traws Pharma is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Vaccinex had 1 more articles in the media than Traws Pharma. MarketBeat recorded 1 mentions for Vaccinex and 0 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.87 beat Vaccinex's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Traws Pharma	Very Positive
Vaccinex	Neutral

Traws Pharma has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Vaccinex's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Vaccinex	N/A	N/A	-383.58%

Summary

Traws Pharma beats Vaccinex on 8 of the 14 factors compared between the two stocks.

How does Vaccinex compare to Reviva Pharmaceuticals?

Vaccinex (NASDAQ:VCNX) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, Vaccinex and Vaccinex both had 1 articles in the media. Vaccinex's average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaccinex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vaccinex's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 10,001.01%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vaccinex has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Reviva Pharmaceuticals has lower revenue, but higher earnings than Vaccinex. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	6.84	-$20.25M	-$48.27	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

Summary

Reviva Pharmaceuticals beats Vaccinex on 7 of the 12 factors compared between the two stocks.

How does Vaccinex compare to Aspire Biopharma?

Vaccinex (NASDAQ:VCNX) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Vaccinex has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	6.84	-$20.25M	-$48.27	N/A
Aspire Biopharma	$10K	807.30	-$24.48M	-$116.67	N/A

In the previous week, Vaccinex and Vaccinex both had 1 articles in the media. Aspire Biopharma's average media sentiment score of 0.62 beat Vaccinex's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaccinex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aspire Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Aspire Biopharma	N/A	N/A	-398.04%

Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market.

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Vaccinex beats Aspire Biopharma on 8 of the 11 factors compared between the two stocks.

How does Vaccinex compare to HCW Biologics?

HCW Biologics (NASDAQ:HCWB) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

HCW Biologics has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

HCW Biologics presently has a consensus price target of $30.00, indicating a potential upside of 597.67%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts clearly believe HCW Biologics is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

HCW Biologics has higher earnings, but lower revenue than Vaccinex. HCW Biologics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	102.34	-$7.96M	-$9.46	N/A
Vaccinex	$388K	6.84	-$20.25M	-$48.27	N/A

In the previous week, HCW Biologics had 8 more articles in the media than Vaccinex. MarketBeat recorded 9 mentions for HCW Biologics and 1 mentions for Vaccinex. HCW Biologics' average media sentiment score of 0.54 beat Vaccinex's score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaccinex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 51.5% of Vaccinex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vaccinex has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Vaccinex's return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Vaccinex	N/A	N/A	-383.58%

Summary

HCW Biologics beats Vaccinex on 10 of the 16 factors compared between the two stocks.

How does Vaccinex compare to Nuvilex?

Nuvilex (NASDAQ:PMCB) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Nuvilex has higher earnings, but lower revenue than Vaccinex. Nuvilex is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Vaccinex	$388K	6.84	-$20.25M	-$48.27	N/A

In the previous week, Vaccinex had 1 more articles in the media than Nuvilex. MarketBeat recorded 1 mentions for Vaccinex and 0 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.87 beat Vaccinex's score of 0.00 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Very Positive
Vaccinex	Neutral

Nuvilex has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nuvilex's return on equity of 2.13% beat Vaccinex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Vaccinex	N/A	N/A	-383.58%

Summary

Nuvilex and Vaccinex tied by winning 6 of the 12 factors compared between the two stocks.

Get Vaccinex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCNX vs. The Competition

Export

Metric	Vaccinex	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.65M	$987.23M	$6.82B	$12.56B
Dividend Yield	N/A	4.84%	2.68%	6.63%
P/E Ratio	-0.02	1.54	27.92	24.67
Price / Sales	6.84	115.83	532.59	97.18
Price / Cash	N/A	20.06	48.59	58.15
Price / Book	-0.39	8.17	10.91	6.45
Net Income	-$20.25M	-$3.96M	$3.57B	$336.71M
7 Day Performance	32.45%	2.96%	2.21%	1.37%
1 Month Performance	32.04%	3.29%	4.58%	1.67%
1 Year Performance	45.82%	51.47%	33.45%	24.05%

Vaccinex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCNX Vaccinex	N/A	$1.02 flat	N/A	+39.7%	$2.65M	$388K	N/A	40
TRAW Traws Pharma	4.1623 of 5 stars	$0.84 -2.2%	$1.00 +18.8%	-47.4%	$8.57M	$2.79M	N/A	17	Positive News Gap Down
RVPH Reviva Pharmaceuticals	2.3116 of 5 stars	$0.64 -4.5%	$66.67 +10,316.7%	-91.4%	$8.39M	N/A	N/A	5	Gap Up
ASBP Aspire Biopharma	0.1501 of 5 stars	$6.44 -1.6%	N/A	-98.2%	$8.37M	$10K	N/A	N/A
HCWB HCW Biologics	4.0905 of 5 stars	$1.15 +3.2%	$5.00 +336.7%	-82.8%	$8.20M	$50K	N/A	40	Stock Split

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCNX) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaccinex (VCNX) Competitors

VCNX vs. TRAW, RVPH, ASBP, HCWB, and PMCB

How does Vaccinex compare to Traws Pharma?

Summary

How does Vaccinex compare to Reviva Pharmaceuticals?

Summary

How does Vaccinex compare to Aspire Biopharma?

Summary

How does Vaccinex compare to HCW Biologics?

Summary

How does Vaccinex compare to Nuvilex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaccinex (VCNX) Competitors

VCNX vs. TRAW, RVPH, ASBP, HCWB, and PMCB

How does Vaccinex compare to Traws Pharma?

Which has higher earnings and valuation, TRAW or VCNX?

Do insiders and institutionals hold more shares of TRAW or VCNX?

Do analysts recommend TRAW or VCNX?

Does the media refer more to TRAW or VCNX?

Which has more risk and volatility, TRAW or VCNX?

Is TRAW or VCNX more profitable?

Summary

How does Vaccinex compare to Reviva Pharmaceuticals?

Does the media favor VCNX or RVPH?

Do insiders & institutionals have more ownership in VCNX or RVPH?

Is VCNX or RVPH more profitable?

Do analysts recommend VCNX or RVPH?

Which has more risk & volatility, VCNX or RVPH?

Which has better valuation and earnings, VCNX or RVPH?

Summary

How does Vaccinex compare to Aspire Biopharma?

Which has better earnings & valuation, VCNX or ASBP?

Does the media prefer VCNX or ASBP?

Do analysts rate VCNX or ASBP?

Is VCNX or ASBP more profitable?

Which has more risk and volatility, VCNX or ASBP?

Do institutionals and insiders hold more shares of VCNX or ASBP?

Summary

How does Vaccinex compare to HCW Biologics?

Which has more volatility and risk, HCWB or VCNX?

Do analysts recommend HCWB or VCNX?

Which has preferable valuation & earnings, HCWB or VCNX?

Does the media refer more to HCWB or VCNX?

Do institutionals & insiders believe in HCWB or VCNX?

Is HCWB or VCNX more profitable?

Summary

How does Vaccinex compare to Nuvilex?

Which has stronger earnings & valuation, PMCB or VCNX?

Does the media favor PMCB or VCNX?

Which has more volatility and risk, PMCB or VCNX?

Do analysts recommend PMCB or VCNX?

Do insiders & institutionals hold more shares of PMCB or VCNX?

Is PMCB or VCNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools